

Filgotinib
Protocol GS-US-417-0301
Gilead Sciences, Inc.

Final
Amendment 1

Appendix 1. Investigator Signature Page

GILEAD SCIENCES, INC.

STUDY ACKNOWLEDGEMENT

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

GS-US-417-0301, Amendment 1 Protocol , 05 July 2016

This protocol has been approved by Gilead Sciences, Inc. The following signature documents this approval.

FRANZISKA MATZKIES, MD
Name (Printed)
Author


Signature

06 - July - 2016
Date

INVESTIGATOR STATEMENT

I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.

I will provide all study personnel under my supervision copies of the protocol and access to all information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they are fully informed about the drugs and the study.

Principal Investigator Name (Printed)

Signature

Date

Site Number

CONFIDENTIAL

Page 100

05 July 2016

